GlaxoSmithKline Acquires Sirtris Pharmaceuticals
GlaxoSmithKline (GSK) completes its acquisition of Sirtris Pharmaceuticals Inc. (Sirtris), for approximately USD720 million (or approx. GBP362 million) through a cash tender offer and merger of USD22.50 (or approx. GBP11.33) per share.
Through the acquisition of Sirtris, GSK has significantly enhanced its metabolic, neurology, immunology and inflammation research efforts by establishing a presence in the field of sirtuins, a recently discovered class of enzymes that is believed to be involved in the ageing process.
Sirtris will become part of GSK's Drug Discovery organization, while continuing to operate from laboratories in
